Tocagen's brain cancer treatment fails late-stage study
(Reuters) - Tocagen Inc said on Thursday its experimental treatment did not prove effective in helping patients with a type of brain cancer to live longer, in a late-stage study.
The California-based company said in the trial its lead product candidate Toca 511 & Toca FC also did not show meaningful superiority in secondary goals compared to standard of care treatment.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
© Copyright Reuters Ltd. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Reuters Ltd.